Shares of Johnson & Johnson (NYSE:JNJ) sold by Chartwell Investment Partners LLC


Chartwell Investment Partners LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating ) by 9.7% during the first quarter, HoldingsChannel reports. The fund owned 165,333 shares of the company’s stock after selling 17,766 shares during the quarter. Johnson & Johnson accounts for about 1.0% of Chartwell Investment Partners LLC’s holdings, making the stock its 7th largest holding. Chartwell Investment Partners LLC’s holdings in Johnson & Johnson were worth $29,302,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Winthrop Advisory Group LLC boosted its position in shares of Johnson & Johnson by 3.7% during the first quarter. Winthrop Advisory Group LLC now owns 9,090 shares of the company’s stock valued at $1,611,000 after purchasing an additional 325 shares during the period. Monte Financial Group LLC boosted its position in shares of Johnson & Johnson by 1.3% during the first quarter. Monte Financial Group LLC now owns 31,275 shares of the company’s stock valued at $5,543,000 after purchasing an additional 398 shares during the period. Allied Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 8.2% during the first quarter. Allied Investment Advisors LLC now owns 47,721 shares of the company’s stock valued at $8,458,000 after buying an additional 3,635 shares during the period. Grant GrossMendelsohn LLC boosted its stake in Johnson & Johnson by 43.1% in the first quarter. Grant GrossMendelsohn LLC now owns 9,557 shares of the company’s stock valued at $1,748,000 after acquiring an additional 2,880 shares in the last quarter. Finally, Five Oceans Advisors boosted its stake in Johnson & Johnson by 1.9% in the first quarter. Five Oceans Advisors now owns 4,384 shares of the company’s stock valued at $777,000 after acquiring an additional 83 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s shares.

Changes in analyst ratings

Several research analysts recently weighed in on JNJ shares. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They assign an “outperform” rating to the stock. Citigroup reduced their price objective on shares of Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Finally, Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Moderate Buy” and an average price target of $191.29, according to MarketBeat.com.

Internal activity

In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the Securities and Exchange Commission, which is available on the SEC’s website. In related news, insider William Haight sold 29,699 shares of the business’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at $14,729,724.88. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. Disclosure of this sale can be found here. Insiders have sold 78,161 shares of company stock worth $13,895,302 over the last ninety days. Insiders own 0.35% of the company’s stock.

Introducing Johnson & Johnson stock

Shares of JNJ stock opened at $178.23 on Friday. The company has a debt-to-equity ratio of 0.39, a quick earnings ratio of 1.14 and a current ratio of 1.39. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The firm has a market cap of $468.99 billion, a P/E ratio of 24.02, a PEG ratio of 3.49 and a beta of 0.63. The firm’s 50-day moving average is $176.76, and its 200-day moving average is $174.33.

Johnson & Johnson (NYSE:JNJ – Get Rating ) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. During the same period last year, the company earned $2.59 earnings per share. The company’s revenue was up 5.0% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 10.21 EPS for the current fiscal year.

Johnson & Johnson increases dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a $1.13 dividend. The ex-dividend date was Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents an annualized dividend of $4.52 and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and markets a variety of health care products worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating) .

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Get news and ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.